HuGE Literature Finder
Records
1
-
3
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. Blood 2015 Dec . Chesnais Virginie, Renneville Aline, Toma Andrea, Lambert Jérôme, Passet Marie, Dumont Florent, Chevret Sylvie, Lejeune Julie, Raimbault Anna, Stamatoullas Aspasia, Rose Christian, Beyne-Rauzy Odile, Delaunay Jacques, Solary Eric, Fenaux Pierre, Dreyfus François, Preudhomme Claude, Kosmider Olivier, Fontenay Michae |
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia 2015 Oct . Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L, Gruson B, Makhoul P C, Chouffi B, Salanoubat C, Benramdane R, Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin A L, Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R, Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux P, Dreyfus |
Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome. BMC medical genetics 2010 11 (1): 163. Ma Wanlong, Kantarjian Hagop, Zhang Ke, Zhang Xi, Wang Xiuqiang, Chen Clifford, Donahue Amber C, Zhang Zhong, Yeh Chen-Hsiung, O'Brien Susan, Garcia-Manero Guillermo, Caporaso Neil, Landgren Ola, Albitar Mah |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jun 22, 2022
- Content source: